CalciMedica, Inc. (CALC) Stock Profile — Insider Trades & Financials

Net Income-$10.8M

EPS$-1.97

Market Cap$9.8M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

A. Leheny

CEO & Executive Director

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.

Founded: 2011
Employees: 16
Headquarters: La Jolla, California, United States

⚡

Core Efficiency

ROE?

162.02%

ROA?

-79.17%

D/E Ratio?

-3.05

📊

Profitability Ratios

Current Ratio?

3.58

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Jul 25, 2026 (in 107 days)

Annual Report (10-K) — Based on filing pattern

Jul 25, 2026

Predicted10-K

Mar 3, 2026

10-KQ4 20255d after period end

Nov 12, 2025

10-QQ3 202543d after period end

Aug 12, 2025

10-QQ2 20256d after period end

May 14, 2025

10-QQ1 20258d after period end

Mar 27, 2025

10-KQ4 20246d after period end

Nov 13, 2024

10-QQ3 20247d after period end

Aug 12, 2024

10-QQ2 20246d after period end

May 13, 2024

10-QQ1 20246d after period end

Loading company sections...

CalciMedica, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness